Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This study aims to assess the efficacy of durvalumab in combination with radiochemotherapy
(FOLFOX and IMRT) and then as maintenance therapy for treating patients with localised
unresectable oesophageal cancer. This is a randomized, French national, multicentre,
comparative phase II trial